SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Merck
Merck
Merck (MRK) Q2 2025 Earnings Call Transcript
By
Fortune Editors
July 29, 2025
Success
Merck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed
By
Orianna Rosa Royle
June 17, 2025
Conferences
Queens of influence: Meet the women shaping Europe’s future
By
Fortune Editors
May 23, 2025
Health
Pharma giant Merck expects Trump’s tariffs to cost the company $200 million
By
Maia Anderson
and
Healthcare Brew
April 25, 2025
Merck (MRK) Q1 2025 Earnings Call Transcript
By
Fortune Editors
April 24, 2025
Health
Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
By
Lindsey Leake
February 7, 2025
Commentary
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
By
Jeffrey Sonnenfeld
and
Steven Tian
February 5, 2025
Health
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
By
Hallie Steiner
February 4, 2025
Merck (MRK) Q4 2024 Earnings Call Transcript
By
Fortune Editors
February 4, 2025
Health
Merck’s $8 billion cancer vaccine faces first U.S. jury trial
By
Bloomberg
and
Peter Blumberg
January 27, 2025
Health
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
By
Lindsey Leake
December 20, 2024
Tech
Merck snags Chinese obesity drug in nearly $2 billion deal
By
Robert Langreth
and
Bloomberg
December 19, 2024
Health
Pneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination
By
Lindsey Leake
October 22, 2024
Leadership
How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute
By
John Kell
October 22, 2024
Health
J&J, Merck, Boston Scientific go on $6.4B buying spree
By
Fiona Rutherford
and
Bloomberg
January 8, 2024
Most Popular
Success
Gen Z is reviving this boring job that millennials and boomers abandoned—and it's helping them land six-figure careers...
By
Preston Fore
Economy
Markets sold off after Powell said six words investors don’t want to hear: ‘Equity prices are fairly highly valued’
By
Jim Edwards
North America
'The frustration is overwhelming': Soybean farmers feel betrayed as Argentina blows a hole in rural America’s $47...
By
Sasha Rogelberg